VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults.

Summary

In a randomized, multicenter Phase 3 trial (n=148), VYC-25L significantly improved chin projection at 24 weeks versus no treatment (Δ G–Sn–Pog 2.97° vs 0.09°; P<.0001), with effects sustained to 52 weeks. Patient- and clinician-reported outcomes (CACRS, GAIS, FACE-Q) markedly favored VYC-25L, and safety was acceptable with mostly mild-to-moderate injection-site reactions.

Key Findings

• Primary endpoint met: mean Δ G–Sn–Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control), P<.0001; improvement maintained to Week 52.
• Responder rates favored VYC-25L for CACRS (78.7% vs 18.8%) and GAIS (92.6% vs 4.2%); FACE-Q Satisfaction with Chin score higher (70.4 vs 34.9).
• Safety acceptable with low procedural pain (mean 2.6/10) and mostly mild-to-moderate injection-site reactions.

Clinical Implications

VYC-25L can be considered for chin retrusion correction with expected 1-year durability, measurable anthropometric gains, and favorable patient satisfaction; monitor for common, mild-to-moderate ISRs.

Limitations

• Comparator was no-treatment rather than a sham or active control, with likely unblinded assessments
• Generalizability may be limited to Chinese adults with moderate-to-severe chin retrusion

Future Directions

Head-to-head trials versus alternative fillers or implants, blinded assessments, and expanded populations to assess generalizability and long-term safety.